Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Childhood rhabdomyosarcoma].

Yasuhide Morikawa1

  • 1Pediatric Surgery, Keio University School of Medicine, Tokyo, Japan.

Nihon Geka Gakkai Zasshi
|July 28, 2005
PubMed
Summary

Childhood rhabdomyosarcoma (RMS) survival in Japan is significantly lower than IRSG rates. Treatment depends on risk classification, with VAC for low/intermediate risk and ongoing trials for high-risk RMS.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Results of a Phase II Trial for Intermediate-Risk Rhabdomyosarcoma Treatment Protocol JRS-I: A Report From the Japan Rhabdomyosarcoma Study Group.

Pediatric blood & cancer·2025
Same author

Results of the JRS-I LRA0401 and LRB0402 Japan Rhabdomyosarcoma Study Group trials for low-risk embryonal rhabdomyosarcoma.

International journal of clinical oncology·2024
Same author

Indications for tracheostomy in children with head and neck lymphatic malformation: analysis of a nationwide survey in Japan.

Surgery today·2019
Same author

Treatment of mediastinal lymphatic malformation in children: an analysis of a nationwide survey in Japan.

Surgery today·2018
Same author

Endoscopic chemocauterization for pyriform sinus fistula in children.

Pediatrics international : official journal of the Japan Pediatric Society·2017
Same author

Fluorescence Visualization of the Enteric Nervous Network in a Chemically Induced Aganglionosis Model.

PloS one·2016

Area of Science:

  • Pediatric Oncology
  • Cancer Research
  • Clinical Trials

Background:

  • Childhood rhabdomyosarcoma (RMS) presents a survival disparity, with Japanese patients experiencing approximately 15% lower five-year survival compared to Intergroup Rhabdomyosarcoma Study Group (IRSG) data.
  • Treatment strategies for RMS are risk-stratified based on tumor histology, site, and staging, influencing patient outcomes.

Purpose of the Study:

  • To highlight the survival gap in Japanese childhood rhabdomyosarcoma patients.
  • To outline current treatment paradigms based on risk classification.
  • To inform about ongoing clinical trials for high-risk RMS.

Main Methods:

  • Review of survival data comparing Japanese outcomes to IRSG benchmarks.
  • Analysis of risk stratification factors influencing treatment decisions.
  • Overview of standard chemotherapy regimens and investigational approaches.

Main Results:

  • Japanese childhood rhabdomyosarcoma patients have a five-year survival rate nearly 15% lower than reported by the IRSG.
  • The VAC (vincristine, dactinomycin, and cyclophosphamide) regimen is standard for low and intermediate-risk RMS.
  • Clinical trials investigating CPT-11 and high-dose chemotherapy for high-risk RMS are in progress.

Conclusions:

  • Addressing the survival deficit in Japanese RMS patients is critical.
  • Tailoring treatment based on precise risk classification is essential for optimizing outcomes.
  • Investigational therapies hold promise for improving survival in high-risk pediatric rhabdomyosarcoma.

Related Experiment Videos